$JSPR News

Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy

William Blair Reinstates Outperform on Jasper Therapeutics

Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants

Jasper Therapeutics Appoints Jeet Mahal As Interim Principal Financial Officer Effective October 9, 2026; Herb Cross Resigns As CFO Effective October 9, 2026

Jasper Therapeutics Announces Key Regulatory and Clinical Appointments

Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Jasper Therapeutics beats Q2 expectations but shares fall after results

Jasper Therapeutics Q2 EPS $(0.10) Beats $(0.26) Estimate

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Piper Sandler Initiates Coverage On Jasper Therapeutics with Overweight Rating, Announces Price Target of $2

Jasper Closes Kira Deal, Extends Cash Runway

Jasper gets a lifeline in merger with immune drugmaker Kira

Jasper Therapeutics Announces Merger with Kira Pharmaceuticals

Jasper Therapeutics Completes The Acquisition Of Kira Pharmaceuticals; Announces $132M Private Placement Of Convertible Preferred Stock; Combined Company Operations Expected To Be Funded Through Second Half Of 2028

Jasper Therapeutics Received Notice Of Non-Compliance With Nasdaq Minimum Bid Requirements On June 3

Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

TD Cowen Downgrades Jasper Therapeutics to Hold

RBC Capital Maintains Sector Perform on Jasper Therapeutics, Lowers Price Target to $3

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update